A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells

Oncotarget

Volumn 7, Issue 4, 2016, Pages 3662-3676

  Matthew, Elizabeth M ^a,b   Zhou, Lanlan ^a,b   Yang, Zhaohai ^c   Dicker, David T ^a,b   Holder, Sheldon L ^a   Lim, Bora ^a,e   Harouaka, Ramdane ^d   Zheng, Si Yang ^d   Drabick, Joseph J ^a   Lamparella, Nicholas E ^a   Truica, Cristina I ^a   El Deiry, Wafik S ^a,b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d The Pennsylvania State University   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carcinoma of unknown primary (CUP); Circulating tumor cells (CTCs); Diagnosis; Immunofluorescence

Indexed keywords

CYTOKERATIN 20; ESTROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER;

ALGORITHM; ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER OF UNKNOWN PRIMARY SITE; CELL POPULATION; CIRCULATING TUMOR CELL; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; MALE; METASTASIS; PRIMARY TUMOR; PROSTATE CANCER; TUMOR DIFFERENTIATION; BREAST NEOPLASMS; CLASSIFICATION; COLORECTAL NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE; LUNG NEOPLASMS; METABOLISM; NEOPLASMS, UNKNOWN PRIMARY; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR EMBOLISM;

ALGORITHMS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS, UNKNOWN PRIMARY; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS;

EID: 84957990887     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6657     Document Type: Article

References (34)

1. Faltas B. Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells. Front Oncol. 2012; 2:68.
2. Giordano A and Cristofanilli M. CTCs in metastatic breast cancer. Recent Results Cancer Res. 2012; 195:193-201.
3. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW and Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351:781-791.
4. Pantel K, Brakenhoff RH and Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008; 8:329-340.
5. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW and Meropol NJ. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009; 20:1223-1229.
6. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG and Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005; 65:713-718.
7. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010; 2:25ra23.
8. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, et al. Inertial focusing for tumor antigen-dependent and-independent sorting of rare circulating tumor cells. Sci Transl Med. 2013; 5:179ra147.
9. Massard C, Loriot Y and Fizazi K. Carcinomas of an unknown primary origin-diagnosis and treatment. Nat Rev Clin Oncol. 2011; 8:701-710.
10. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009; 9:302-312.
11. Zhou L and El-Deiry WS. Multispectral fluorescence imaging. J Nucl Med. 2009; 50:1563-1 566.
12. Zrazhevskiy P and Gao X. Quantum dot imaging platform for single-cell molecular profiling. Nat Commun. 2013; 4:1619.
13. Miller MC, Doyle GV and Terstappen LW. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol. 2010; 2010:617421.
14. Attard G and de Bono JS. Utilizing circulating tumor cells: challenges and pitfalls. Curr Opin Genet Dev. 2011; 21:50-58.
15. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M and Pantel K. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13:920-928.
16. Gallant JN, Matthew EM, Cheng H, Harouaka R, Lamparella NE, Kunkel M, Yang Z, Harvey HA, Cream LV, Kumar SM, Robertson GP, Zheng S, Drabick JJ, Truica CI and El-Deiry WS. Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle. 2013; 12:2132-2143.
17. Harouaka RA, Zhou MD, Yeh YT, Khan WJ, Das A, Liu X, Christ CC, Dicker DT, Baney TS, Kaifi JT, Belani CP, Truica CI, El-Deiry WS, Allerton JP and Zheng SY. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clin Chem. 2014; 60:323-333.
18. Chu P, Wu E and Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000; 13:962-972.
19. Hameed O and Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol. 2005; 22:88-104.
20. Kaufmann O and Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000; 36:8-16.
21. Pavlidis N, Briasoulis E, Hainsworth J and Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003; 39:1990-2005.
22. Sheridan T, Herawi M, Epstein JI and Illei PB. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol. 2007; 31:1351-1355.
23. Stein BS, Vangore S and Petersen RO. Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites. Urology. 1984; 24:146-152.
24. Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer. 1999; 85:171-177.
25. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN and Oien KA. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005; 11:3766-3772.
26. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360:1320-1328.
27. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893-2917.
28. Bassily NH, Vallorosi CJ, Akdas G, Montie JE and Rubin MA. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol. 2000; 113:383-388.
29. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002; 117:471-477.
30. Aktas B, Muller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, Rack B, Schneeweiss A and Fehm T. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol. 2011; 122:356-360.
31. Babayan A, Hannemann J, Spotter J, Muller V, Pantel K and Joosse SA. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One. 2013; 8:e75038.
32. Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B, Naso G, Agliano AM, Cortesi E and Gazzaniga P. Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J Cell Mol Med. 2011; 15:1066-1070.
33. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ and Garcia-Blanco MA. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011; 9:997-1007.
34. Papsidero LD, Croghan GA, Asirwatham J, Gaeta J, Abenoza P, Englander L and Valenzuela L. Immunohistochemical demonstration of prostate-specific antigen in metastases with the use of monoclonal antibody F5. Am J Pathol. 1985; 121:451-454.